Isofol Medical AB

As of June 30, 2026, Isofol Medical AB carries a market capitalization of 235.88M, placing it among publicly traded companies globally. Its enterprise value stands at 121.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Isofol Medical AB's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Isofol Medical AB has 320.49M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Isofol Medical AB maintains a current ratio of 5.17, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Isofol Medical AB posted a negative return on equity (ROE) of -78.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -60.35, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 5.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Isofol Medical AB's stock has gained approximately 35.17% over the past 52 weeks. The 50-day moving average sits at 0.79, while the 200-day moving average is 0.73.

Over the twelve months ended June 30, 2026, Isofol Medical AB generated - - in revenue and converted that into -56.63M in net income, yielding earnings per share of -0.20. EBITDA reached -58.85M, while operating income came in at -58.85M.

These figures are as of June 30, 2026. Total book value stands at 95.01M, with working capital of 95.64M providing operational flexibility.

Isofol Medical AB produced -52.64M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -25.54: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -43.23, meaning Isofol Medical AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Isofol Medical AB's most recent stock split took place on June 13, 2025.

As of June 30, 2026, Isofol Medical AB has an Altman Z-Score of -9.19, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.